We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00269373
First Posted: December 23, 2005
Last Update Posted: February 22, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Gedske Daugaard, Rigshospitalet, Denmark
December 22, 2005
December 23, 2005
February 22, 2012
December 2005
February 2012   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00269373 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors
PET-CT Scan as a Diagnostic Method in Unknown Primary Tumors
Is PET-CT scan better than PET or CT alone in diagnosing primary tumours in patients with unknown primary tumors? Can information obtained with PET-CT replace other clinical and radiological investigations? Is PET/CT cost-effective?

Patients who fulfill the international definition of unknown primary tumors can be included, except:

  • Young men (<55 years) with growing mid-line tumors where a germ cell tumor could be expected will not be included.
  • Patients with lymph-node metastases with squamous cell carcinoma in the head and neck region will not be included.
  • Women with adenocarcinoma in lymph nodes in the axilla will not be included.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with unknown tumors
Unknown Primary Tumor
Procedure: PET-CT
no drugs included
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
136
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Unknown primary tumors

Exclusion Criteria:

  • Young men (<55 years) with growing mid-line tumors where a germ cell tumor could be expected will not be included.
  • Patients with lymph-node metastases with squamous cell carcinoma in the head and neck region will not be included
  • Women with adenocarcinoma in lymph nodes in the axilla will not be included
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT00269373
01 283694
No
Not Provided
Not Provided
Gedske Daugaard, Rigshospitalet, Denmark
Rigshospitalet, Denmark
Not Provided
Principal Investigator: Gedske Daugaard Rigshospitalet, Denmark
Rigshospitalet, Denmark
February 2012